Mirion’s Chief Executive Officer, Thomas Logan, will reassume responsibilities of Medical Group President until permanent successor is named
Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced that Michael Rossi has informed the Company of his decision to resign as Medical Group President, effective November 1, 2023, in order to assume a CEO role at another public company.
Mirion’s Chief Executive Officer, Thomas Logan, will reassume the responsibilities of Medical Group President until a permanent successor is named. Mr. Logan had previously served as acting Medical Group President through much of 2022.
“Mike has been a valued member of the Mirion executive team for the last year, and we are grateful for his contributions,” said Mr. Logan. “All of us at Mirion wish Mike well as he takes this next step in his career as a public company CEO.”
About Mirion
Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,700 people and operates in 12 countries. Learn more at mirion.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231018343266/en/
Contacts
For investor inquiries:
Jerry Estes
ir@mirion.com
For media inquiries:
Erin Schesny
media@mirion.com
